Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism - a Pilot Study

NCT05686993 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT05686993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism - a Pilot Study
Lead sponsor
Queen Mary University of London
Phase
Not applicable
Overall status
Completed
Start date
April 24, 2023
Completion date
September 6, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine hypertension, primary aldosteronism